Pfizer Inc. and China’s Innovent Biologics Inc. signed a global agreement worth as much as $10.5 billion to develop cancer ...

May 29 (Reuters) - China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and ...

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer ...

Learn more Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer ...

Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and ...

The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet.

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational ...

Pfizer and Innovent Biologics signed a licensing agreement to research and develop 12 cancer medicines. The agreement includes licensing, co-development and co-commercialization across the ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic castration-resistant prostate cancer (mCRPC) ...

Pfizer posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as recently launched ...

Pfizer and Innovent Biologics ink strategic collaboration to accelerate development of innovative oncology medicines: New York Saturday, May 30, 2026, 09:00 Hrs [IST] Pfizer Inc.